|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20 Pt 1
|
|
pubmed:dateCreated |
2006-10-25
|
|
pubmed:abstractText |
Human Valpha24 natural killer T (Valpha24 NKT) cells bearing an invariant Valpha24JalphaQ antigen receptor are activated by a glicolipid ligand alpha-galactosylceramide (alphaGalCer; KRN7000) in a CD1d-dependent manner. The human Valpha24 NKT cells activated with alphaGalCer and interleukin-2 have been shown to produce large amounts of cytokines, such as IFN-gamma, and also exerting a potent killing activity against various tumor cell lines. We did a phase I study with autologous activated Valpha24 NKT cell therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:FujiiShin-ichiroS,
pubmed-author:FujisawaTakehikoT,
pubmed-author:HanaokaHidekiH,
pubmed-author:HoriguchiShigetoshiS,
pubmed-author:IizasaToshihikoT,
pubmed-author:IshikawaAkiA,
pubmed-author:IshikawaEiichiE,
pubmed-author:MotohashiShinichiroS,
pubmed-author:NakayamaToshinoriT,
pubmed-author:OkamotoYoshitakaY,
pubmed-author:OtsujiMizutoM,
pubmed-author:ShimizuNaomiN,
pubmed-author:TaniguchiMasaruM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6079-86
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17028247-Adult,
pubmed-meshheading:17028247-Aged,
pubmed-meshheading:17028247-Aged, 80 and over,
pubmed-meshheading:17028247-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17028247-Humans,
pubmed-meshheading:17028247-Killer Cells, Natural,
pubmed-meshheading:17028247-Lung Neoplasms,
pubmed-meshheading:17028247-Lymphocyte Activation,
pubmed-meshheading:17028247-Lymphocyte Transfusion,
pubmed-meshheading:17028247-Middle Aged,
pubmed-meshheading:17028247-Patient Selection,
pubmed-meshheading:17028247-Recurrence
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
|
|
pubmed:affiliation |
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
